Key result
Single-dose aspirin rapidly inhibits platelet activation and lowers PAI-1 for up to 4 days.
Why the study?
Does a single oral dose of aspirin inhibit platelet function and reduce plasma PAI-1 levels in healthy volunteers?
Does a single oral dose of aspirin inhibit platelet function and reduce plasma PAI-1 levels in healthy volunteers?
A single 650 mg oral dose of aspirin rapidly inhibits arachidonic acid-induced platelet activation and reduces plasma PAI-1 for up to 4 days, but may cause a rebound response to other platelet agonists.
Answers are grounded in this paper and cite their sources.
Should not change practice; hypothesis-generating for sustained platelet and PAI-1 effects in healthy volunteers.
Previous reports documented the inhibitory efficacy of different doses of aspirin on arachidonic acid (AA)-induced platelet aggregation, however, the sensitivity of platelets toward other agonists as well as the effects of aspirin on platelet and plasma plasminogen activator inhibitor-1 (PAI-1) release and levels were not investigated. Hence, the present study was undertaken to investigate the effect and duration of action of a single oral dose (650 mg) of aspirin on human platelet functions (n = 34, normal healthy male and female volunteers) including aggregation, fibrinogen binding and PAI-1 release, and on the plasma level of PAI-1. Aspirin demonstrated a rapid onset of action (at 2 h after ingestion) in specifically inhibiting ex vivo AA-mediated functions including (a) fibrinogen binding to gel-purified platelets, (b) platelet aggregation, and (c) platelet PAI-1 release. A peak reduction of plasma PAI-1 level at 2 h was demonstrated as well. The effect of aspirin on the ex vivo AA-mediated effects (a-c) was shown to last for up to 4 days. However, aspirin treatment resulted in a rebound effect in platelet function (a-c) to other platelet agonists such as adenosine diphosphate or the combination of agonists including adenosine diphosphate, epinephrine, and AA. In conclusion, a single oral dose of aspirin has long-acting effects on AA-induced platelet activation and reduces plasma levels of PAI-1 as well.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Mousa et al. (2008) studied Healthy volunteers (n=34). Aspirin was evaluated on Ex vivo arachidonic acid-mediated platelet functions and plasma PAI-1 levels. A single oral dose of aspirin rapidly inhibited arachidonic acid-induced platelet activation and reduced plasma PAI-1 levels for up to 4 days in healthy volunteers.
Synapse has enriched 10 related papers. Consider them for comparative context: